{{Rsnum
|rsid=9934438
|Gene=VKORC1
|Chromosome=16
|position=31093557
|Orientation=plus
|GMAF=0.4679
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=VKORC1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 19.5 | 40.7 | 39.8
| HCB | 90.5 | 9.5 | 0.0
| JPT | 81.4 | 18.6 | 0.0
| YRI | 0.0 | 6.1 | 93.9
| ASW | 5.3 | 10.5 | 84.2
| CHB | 90.5 | 9.5 | 0.0
| CHD | 82.6 | 16.5 | 0.9
| GIH | 2.0 | 32.7 | 65.3
| LWK | 0.0 | 11.8 | 88.2
| MEX | 22.4 | 48.3 | 29.3
| MKK | 1.9 | 28.2 | 69.9
| TSI | 21.6 | 51.0 | 27.5
| HapMapRevision=28
}}{{PMID|18218987}} risk of aortic calcification was calculated, adjusted for potential confounders. The T allele frequency of the VKORC1 1173C>T polymorphism was 38.8%. 1185 (37.2%) persons were homozygous CC, 1529 (48,0%) were heterozygous CT and 473 (14.8%) were homozygous TT. Persons with at least one T-allele had a statistically significant 19% (95% CI 2 to 40%) risk increase of calcification of the aortic far wall compared to CC homozygous persons

{{ neighbor
| rsid = 8050894
| distance = 369
}}

{{omim
|desc=COUMARIN RESISTANCE
|id=122700
|rsnum=9934438
}}

{{omim
|desc=VITAMIN K EPOXIDE REDUCTASE COMPLEX, SUBUNIT 1; VKORC1
|id=608547
|rsnum=9934438
}}

{{PharmGKB
|RSID=rs9934438
|Name_s=VKORC1:C1173T
|Gene_s=VKORC1
|Feature=Intron
|Evidence=PubMed ID:19270263
|Annotation=Double homozygous VKORC1 1173T/T, CYP4F2 433Val/Val (n = 5) showed the highest INR (3.1; 2.0-4.7) and required the lowest acenocoumarol dose (11 &#177; 3 mg/week) The addition of the V433M genotype to the VKORC1 genotype raised the R2 from 8% to 14% for INR, and from 12% to 19% for acenocoumarol dose requirements.
|Drugs=acenocoumarol
|Drug Classes=
|Diseases=Arteriosclerosis; Heart Diseases; Hemorrhage; Intracranial Hemorrhages; Myocardial Infarction; Peripheral Vascular Diseases; Pulmonary Embolism; Stroke; Thromboembolism; venous thromboembolism; Venous Thrombosis
|Curation Level=Curated
|PharmGKB Accession ID=PA165110362
}}

{{PharmGKB
|RSID=rs9934438
|Name_s=VKORC1:C6484T; VKORC1:1173C>T
|Gene_s=VKORC1
|Feature=Intron
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/vkorc1/variant.jsp#ImportantVariantInformationforVKORC1-6484
|Annotation=Tagging SNP for low dose phenotype
|Drugs=warfarin
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145139
}}

{{PharmGKB
|RSID=rs9934438
|Name_s=VKORC1: 1173C>T
|Gene_s=VKORC1
|Feature=Intron
|Evidence=PubMed ID:20203262
|Annotation=Risk or phenotype-associated allele: minor allele T was associated with decrease in warfarin dose requirements. Phenotype: In Asians, Blacks or Whites, this SNP (or equivalently, rs9923231(-1639G>A)) captures the variability in warfarin dose attributable to VKORC1. Study size/population/ethnicity: 1103 Asians, 670 Blacks, 3113 Whites. Type of association: CO; GN; PD
|Drugs=warfarin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291602
}}

{{PMID Auto
|PMID=21179439
|Title=VKORC1 common variation and bone mineral density in the Third National Health and Nutrition Examination Survey
|OA=1
}}

{{PMID Auto
|PMID=22118051
|Title=Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity
}}

{{PMID Auto
|PMID=16270629
|Title=VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation.
}}

{{PMID Auto
|PMID=17048007
|Title=Association of warfarin dose with genes involved in its action and metabolism.
|OA=1
}}

{{PMID Auto
|PMID=18252229
|Title=Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
|OA=1
}}

{{PMID Auto
|PMID=18466099
|Title=Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
|OA=1
}}

{{PMID Auto
|PMID=18523153
|Title=Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.
|OA=1
}}

{{PMID Auto
|PMID=18559094
|Title=Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction.
|OA=1
}}

{{PMID Auto
|PMID=18596683
|Title=Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans.
|OA=1
}}

{{PMID Auto
|PMID=18680736
|Title=Genetic factors contribute to patient-specific warfarin dose for Han Chinese.
}}

{{PMID Auto
|PMID=18752379
|Title=Warfarin pharmacogenetics.
|OA=1
}}

{{PMID Auto
|PMID=18809808
|Title=Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics.
|OA=1
}}

{{PMID Auto
|PMID=18813101
|Title=Impact of VKORC1 haplotypes on long-term graft function in kidney transplantation.
}}

{{PMID Auto
|PMID=18855533
|Title=VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
|OA=1
}}

{{PMID Auto
|PMID=19074728
|Title=Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.
|OA=1
}}

{{PMID Auto
|PMID=19172700
|Title=A genotyping method for VKORC1 1173C > T by Pyrosequencing technology.
}}

{{PMID Auto
|PMID=19228618
|Title=Estimation of the warfarin dose with clinical and pharmacogenetic data.
|OA=1
}}

{{PMID Auto
|PMID=19300499
|Title=A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
|OA=1
}}

{{PMID Auto
|PMID=19955245
|Title=Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.
|OA=1
}}

{{PMID Auto
|PMID=20585445
|Title=A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.
|OA=1
}}

{{PMID Auto
|PMID=20733952
|Title=Warfarin genotyping using three different platforms.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs9934438
|overall_frequency_n=42
|overall_frequency_d=126
|overall_frequency=0.333333
|n_genomes=24
|n_genomes_annotated=0
|n_haplomes=38
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23124848
|Title=SNPs in VKORC1 are risk factors for systemic lupus erythematosus in asians
|OA=1
}}

{{PMID Auto
|PMID=23662025
|Title=Genetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population
|OA=1
}}

{{PMID Auto
|PMID=24324947
|Title=VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients
|OA=1
}}

{{PMID Auto
|PMID=24602049
|Title=Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves
}}

{{PMID Auto
|PMID=23691226
|Title=Novel associations of VKORC1 variants with higher acenocoumarol requirements.
|OA=1
}}

{{PMID Auto
|PMID=24966969
|Title=High resolution melting method to detect single nucleotide polymorphism of VKORC1 and CYP2C9
}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}